

Refine Search

Search Results -

| Terms | Documents |
|------------|-----------|
| L3 and fiv | 4 |

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Search History

 DATE: Sunday, October 30, 2005 [Printable Copy](#) [Create Case](#)

| <u>Set</u> <u>Name</u> side by side | <u>Query</u> | <u>Hit</u> <u>Count</u> | <u>Set</u> <u>Name</u> result set |
|---|---|----------------------------|---|
| <i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i> | | | |
| <u>L7</u> | l3 and fiv | 4 | <u>L7</u> |
| <i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i> | | | |
| <u>L6</u> | l3 and therapeutic\$ | 13 | <u>L6</u> |
| <u>L5</u> | l3 and therpaeutic\$ | 0 | <u>L5</u> |
| <u>L4</u> | LCMV near10 (envelop\$ or glycoprotein\$) near20 inducib\$ near5 promoter\$ | 0 | <u>L4</u> |
| <u>L3</u> | LCMV near10 (envelop\$ or glycoprotein\$) and inducib\$ near5 promoter\$ | 13 | <u>L3</u> |
| <u>L2</u> | LCMV and inducib\$ near5 promoter\$ | 102 | <u>L2</u> |
| <u>L1</u> | LCMV and inducib\$ | 142 | <u>L1</u> |

END OF SEARCH HISTORY

BEGIN 5, 6, 55, 154, 155, 156, 312, 399, BIOTECH, BIOSCI

Set Items Description

--- ----

?

S (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND PSEUDOTYP?

>>>File 5 processing for VIR? stopped at VIROMAX

>>>File 155 processing for VIR? stopped at VIRUMIN

>>>File 73 processing for VIR? stopped at VIRUSTOMYCIN

Processing

Processed 10 of 39 files ...

>>>File 144 processing for VIR? stopped at VIRTUOZO

>>>File 50 processing for VIR? stopped at VIRUSVAKTSINOI

Completed processing all files

| | | |
|----|---------|--|
| | 6497 | LCMV |
| | 283843 | LYMPHOCYTIC |
| | 16208 | CHORIOMENINGITIS |
| | 6354634 | VIR? |
| | 10155 | LYMPHOCYTIC(N)CHORIOMENINGITIS(N)VIR? |
| | 11588 | PSEUDOTYP? |
| S1 | 174 | (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND PSEUDOTYP? |

?

S S1 AND (WE54 OR WE (N) 54 OR HP1 OR HPI)

Processed 10 of 39 files ...

Processing

Completed processing all files

| | | |
|----|----------|--|
| | 174 | S1 |
| | 58 | WE54 |
| | 19101270 | WE |
| | 987561 | 54 |
| | 685 | WE(N)54 |
| | 5424 | HP1 |
| | 5650 | HPI |
| S2 | 13 | S1 AND (WE54 OR WE (N) 54 OR HP1 OR HPI) |

?

RD S2

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

| | | |
|----|---|----------------------|
| S3 | 7 | RD S2 (unique items) |
|----|---|----------------------|

?

Display 3/3/1 (Item 1 from file: 154)

DIALOG(R)File 154:MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

18202725 PMID: 15727934

The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain.

Stein Colleen S; Martins Ines; Davidson Beverly L

Program in Gene Therapy, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (United States) Mar 2005, 11 (3) p382-9, ISSN 1525-0016

Journal Code: 100890581

Contract/Grant No.: DK54759; DK; NIDDK; NS34568; NS; NINDS

Publishing Model Print

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

- end of record -

?

Display 3/3/2 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

142476299 CA: 142(26)476299z PATENT

Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery

INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen
LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609

APPLICATION: US 2004993319 (20041119) *US 2003718262 (20031120)

PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO

LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;

C07K-014/005B; C12N-015/86B

- end of record -

?

Display 3/3/3 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

137016445 CA: 137(2)16445g JOURNAL

Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range

AUTHOR(S): Beyer, Winfried R.; Westphal, Manfred; Ostertag, Wolfram; Von Laer, Dorothee

LOCATION: Heinrich-Pette-Institut fur Experimentelle Virologie und Immunologie an der Universitat Hamburg, Hamburg, Germany, D-20251

JOURNAL: J. Virol. (Journal of Virology) DATE: 2002 VOLUME: 76

NUMBER: 3 PAGES: 1488-1495 CODEN: JOVIAM ISSN: 0022-538X LANGUAGE: English PUBLISHER: American Society for Microbiology

- end of record -

?

Display 3/3/4 (Item 1 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00624119

IDENTIFYING NO.: 2P01HL051670-11 0005 AGENCY CODE: CRISP

Targeting Entry in Epithelia with ICMV-FIV

PRINCIPAL INVESTIGATOR: MCCRAY, PAUL B, JR

ADDRESS: PAUL-MCCRAY@UIOWA.EDU UNIVERSITY OF IOWA 616 MEDICAL RESEARCH CENTER IOWA CITY, IA 52242

PERFORMING ORG.: UNIVERSITY OF IOWA, IOWA CITY, IOWA

SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

DATES: 2009/01/97 TO 2003/31/09 FY : 2004

- end of record -

?

Display 3/3/5 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0372996 DBR Accession No.: 2005-18702 PATENT

Transducing a nervous system cell with a transgene comprises contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene - virus vector expression in host cell for use in disease therapy and gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L; STEIN C

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L; STEIN C 2005

PATENT NUMBER: US 20050123517 PATENT DATE: 20050609 WPI ACCESSION NO.: 2005-416924 (200542)

PRIORITY APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

NATIONAL APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

LANGUAGE: English

- end of record -

?

Display 3/3/6 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.: 2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

Display 3/3/7 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0329671 DBR Accession No.: 2004-01963 PATENT

New chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a heterologous amino acid sequence, useful for inducing an immune response against Ebola virus, bacteria, or fungi - involving vector-mediated gene transfer and expression in host cell for use in therapy

AUTHOR: WILSON J M; MEDINA M F C; KOBINGER G

PATENT ASSIGNEE: UNIV PENNSYLVANIA 2003

PATENT NUMBER: WO 200392582 PATENT DATE: 20031113 WPI ACCESSION NO.: 2004-011795 (200401)

PRIORITY APPLIC. NO.: US 427752 APPLIC. DATE: 20021120
NATIONAL APPLIC. NO.: WO 2003US11494 APPLIC. DATE: 20030428
LANGUAGE: English

- end of record -

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0329671 DBR Accession No.: 2004-01963 PATENT

New chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a heterologous amino acid sequence, useful for inducing an immune response against Ebola virus, bacteria, or fungi - involving vector-mediated gene transfer and expression in host cell for use in therapy

AUTHOR: WILSON J M; MEDINA M F C; KOBINGER G

PATENT ASSIGNEE: UNIV PENNSYLVANIA 2003

PATENT NUMBER: WO 200392582 PATENT DATE: 20031113 WPI ACCESSION NO.:
2004-011795 (200401)

PRIORITY APPLIC. NO.: US 427752 APPLIC. DATE: 20021120

NATIONAL APPLIC. NO.: WO 2003US11494 APPLIC. DATE: 20030428

LANGUAGE: English

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

heterologous amino acid sequence, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a nucleic acid molecule encoding a chimeric Ebola protein defined above; (2) a host cell comprising the chimeric Ebola protein or nucleic acid molecule encoding the protein; (3) a method of inducing an immune response against Ebola by delivering a composition comprising the chimeric Ebola protein or nucleic acid molecule encoding the protein; (4) a recombinant virus having a chimeric Ebola envelope protein and a minigene; (5) a host cell containing the recombinant virus; (6) a method of treating a patient with a selected molecule by transducing the cells of the patient with the recombinant virus above; (7) a method of delivering a molecule to the apical cells of the lung by administering a recombinant virus above intratracheally; (8) an immunogenic composition comprising a DNA molecule encoding a chimeric Ebola envelope protein above under the control of sequences which direct its expression in a host cell, and a carrier; and (9) an

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

immunogenic composition comprising an Ebola envelope protein defined above, and a carrier. BIOTECHNOLOGY - Preferred Protein: The chimeric Ebola envelope protein contains a wild-type Ebola glycoprotein-binding domain. The heterologous amino acid sequence is an Ebola glycoprotein

sequence, which is non-contiguous with the binding domain in the wild-type Ebola. The chimeric Ebola envelope protein comprises an Ebola signal peptide and an Ebola binding domain having a deletion in the native Ebola region between the signal peptide and the binding domain, where the deletion is about 1-50 amino acids between the signal peptide and the binding domain. Alternatively, the chimeric Ebola envelope protein comprises a deletion of the complete Ebola signal peptide or its portion, where the deletion of all or a portion of the carboxy terminus of the signal peptide comprises a deletion of about 1-30 amino acids, or a deletion of all or a portion of the Ebola transmembrane consisting of a deletion of about 1-23 amino acids. The chimeric Ebola envelope protein may also comprise a deletion of all or a portion of

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

the Ebola cytoplasmic domain, which comprises a deletion of about 1-3 amino acids. The chimeric Ebola envelope protein comprises a transmembrane domain from a heterologous protein and a cytoplasmic domain, where the heterologous amino acid sequence from a non-Ebola protein. The heterologous amino acid sequence is selected from a Vesicular Stomatitis Virus protein, a human immunodeficiency virus transmembrane domain, a murine leukemia virus, and a Lymphocytic Choriomeningitis virus. The chimeric Ebola envelope protein is selected from: (a) NTDL1, amino acids 1-366 fused to amino acids 497 to 676 of the Ebola glycoprotein comprising a sequence of 676 amino acids (SEQ ID NO: 1); (b) NTDL2, amino acids 1-366 fused to amino acids 502-676 SEQ ID NO: 1; (c) NTDL3, amino acids 1-370 fused to amino acids 492-676 of SEQ ID NO: 1; (d) NTDL4, amino acids 1-311 fused to amino acids 497-676 SEQ ID NO: 1; (e) NTDL5, amino acids 1-287 fused to amino acids 497-676 of SEQ ID NO: 1; (f) NTDL6, amino acids 1-279 fused to amino acids 497-676 of SEQ ID NO: 1; (g) NTDL7, amino acids 1-267 fused to amino acids

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

497-676 SEQ ID NO: 1; (h) NTDL8, amino acids 1-258 fused to amino acids 497-676 SEQ ID NO: 1; (i) NTDL9, amino acids 1-232 fused to amino acids 497-676 of SEQ ID NO: 1; (j) NTDL11, amino acids 1-231 fused to amino acids 497-676 of SEQ ID NO: 1; (k) DELTAN, amino acids 1-31 fused to amino acids 172-676 of SEQ ID NO: 1; (l) EboDELTA5S, amino acids 1-220 of the Ebola glycoprotein comprising a sequence of 364 amino acids (SEQ ID NO: 2); (m) EboDELTA6S, amino acids 1-361 of SEQ ID NO: 2; (n) EboDELTA7S, amino acids 1-628 of SEQ ID NO: 2; and (o) EboDELTA8S, amino acids 1-311 fused to amino acids 497-664 of SEQ ID NO: 2; (p) VTC, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 463-511 of a sequence of 856 amino acids (SEQ ID NO: 3) given in the specification; (q) -2aa, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 465-511 of SEQ ID NO: 3; (r) +2aa, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 461-511 of SEQ ID NO: 3; (s) +16aa, amino acids 1-672 of SEQ ID NO: 1 fused amino acids 447-511 of SEQ ID NO: 3; (t) +23aa, amino acids 1 - 672 of SEQ ID NO: 1 fused to amino acids

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

440-511 of SEQ ID NO: 3; (u) +42aa, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 421-511 of SEQ ID NO: 3; (v) V/C, amino acids 1-672 of SEQ ID NO: 1 fused to amino acids 483-511 of SEQ ID NO: 3; (w) V/2C, amino acids 1-676 of SEQ ID NO: 1 fused to amino acids 483-511 of SEQ ID NO: 3; (x) V/T, amino acids 1-650 of SEQ ID NO: 1 fused to amino acids 463-482 of SEQ ID NO: 3; (y) DELTAInt, amino acids 1-629 of SEQ ID NO: 1 fused to amino acids sequences 463-511 of SEQ ID NO: 3; (z) DELTAImm, amino acids 1-563 of SEQ ID NO: 1 fused to amino acids 463-511 of SEQ ID NO: 3; (a) VE, amino acids 180-350 of SEQ ID NO: 1 in the VS-G envelope, SEQ ID NO: 3; (b) H/TC, amino acids 1-650 of SEQ ID NO: 1 fused to amino acids 661-856 of a sequence of 856 amino acids (SEQ ID NO: 8); (c) M/C, amino acids 1-650 of SEQ ID NO: 1 fused to a VSV-G transmembrane domain, 465-482 of SEQ ID NO: 3, and an MLV-GP cytoplasmic domain, amino acids 634-649 of a 654-amino acid sequence (SEQ ID NO: 6); (d) M/CR, amino acids 1-650 of SEQ ID NO: 1 fused to a VSV-G transmembrane domain, 465-482 of SEQ ID NO: 3, an MLV-GP

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

cytoplasmic domain, amino acids 634-649 of SEQ ID NO: 6, and an R peptide of MLV-GP, amino acids 650-665 of MLV-GP, SEQ ID NO: 6; and (e) L/TC, amino acids 1-650 of SEQ ID NO: 1 fused to amino acids 439-498 of LCMV-GP comprising a sequence of 498 amino acids (SEQ ID NO: 9). Preferred Nucleic Acid: The nucleic acid molecule is a plasmid, a viral vector, or an adenoviral vector. Preferred Method: In inducing an immune response against Ebola, the composition is delivered intramuscularly or orally. In treating a patient with a selected molecule, the cells transduced are lung cells, dendritic cells and macrophages. The recombinant virus is administered directly to the patient. The transgene is a CFTR gene and the recombinant virus is administered intratracheally. The cells of the patient are transduced ex vivo, and are re-infused into the patient having cancer. Preferred Virus: The minigene is a lentivirus minigene comprising Rev response element (RRE) sequences, where the lentivirus sequences are selected from human immunodeficiency virus (HIV) vector, simian immunodeficiency

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

virus (SIV) vector, caprine arthritis and encephalitis virus, equine infectious anemia virus, visna virus, and feline immunodeficiency virus (FIV) vector, preferably an HIV. The 5' and 3' LTR sequences are self-reactivating, and contain a deletion in the U3 region. Preferred Composition: The immunogenic composition comprises a recombinant virus comprising the DNA molecule or a wild-type Ebola G or S protein. ACTIVITY - Virucide; Antibacterial; Antiparasitic; Cytostatic. MECHANISM OF ACTION - Vaccine. The cellular immune response to Ebola envelope in C57BL/6 mice was evaluated 8 days after a single

intramuscular administration of 581010 particles of C7-LacZ or C7-Ebola envelope variant per animal. Mice were vaccinated with 5x1010 particles of C7 encoding LacZ or Ebola envelope variant. Splenic lymphocytes from immunized mice were collected 8 days post vaccination, and stimulated in vitro with feeder cells. standard 5-hour CTL assays were performed using 51Cr-labeled syngeneic C57 cells transfected with an expressor of EboZ. A positive MHC-restricted cytotoxic T lymphocyte response was

-more-

?

Display 3/9/7 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

observed from all AdPan-7 encoding for Ebola envelope variants with a higher response from NTDL2, NTDL3 or NTDL4 immunized mice. Effector cells from C7 encoding Ebola envelope variant immunized mice recognized EboZ transfected target cells and gave recall CTL responses up to 30% specific lysis. Less than 5% lysis was seen with effector cells from naive or LacZ immunized control mice confirming that lysis was specific for Ebola envelope antigens. USE - The recombinant virus is useful in preparing a medicament (claimed). The chimeric Ebola envelope protein is useful as an antigen for inducing an immune response against Ebola virus, and for generating a chimeric Ebola-pseudotyped virus, which delivers a selected molecule to a target cell. The proteins may be used to provide heterologous envelope to any vector derived from a viral source, which natively contain has an envelope. The protein may further be used to immunize a (non-)human animal against other pathogens including bacteria, fungi, parasitic microorganisms or multicellular parasites, which infect human and non-human vertebrates, or from a

-more-

?

S (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND (RESIDUE (3N) 153 OR POSIT

>>>File 5 processing for VIR? stopped at VIROMAX

>>>File 155 processing for VIR? stopped at VIRUMIN

>>>File 73 processing for VIR? stopped at VIRUSTOMYCIN

Processing

Processed 10 of 39 files ...

>>>File 144 processing for VIR? stopped at VIRTUOZO

>>>File 50 processing for VIR? stopped at VIRUSVAKTSINOI

Completed processing all files

| | |
|---------|---|
| 6497 | LCMV |
| 283843 | LYMPHOCYTIC |
| 16208 | CHORIOMENINGITIS |
| 6354634 | VIR? |
| 10155 | LYMPHOCYTIC(N)CHORIOMENINGITIS(N)VIR? |
| 762448 | RESIDUE |
| 103205 | 153 |
| 335 | RESIDUE(3N)153 |
| 1842774 | POSITION |
| 103205 | 153 |
| 378 | POSITION(3N)153 |
| 266453 | PHENYLALANINE |
| 103205 | 153 |
| 28 | PHENYLALANINE(3N)153 |
| S4 | 3 (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND (RESIDUE (3N) 153 OR POSITION (3N) 153 OR PHENYLALANINE (3N) 153) |

?

Display 4/3/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

142476299 CA: 142(26)476299z PATENT

Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery

INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen
LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609

APPLICATION: US 2004993319 (20041119) *US 2003718262 (20031120)

PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO

LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;
C07K-014/005B; C12N-015/86B

- end of record -

?

Display 4/3/2 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

142476282 CA: 142(26)476282p PATENT

Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery

INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.
LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050112096 A1 DATE: 20050526

APPLICATION: US 2003718262 (20031120)

PAGES: 25 pp. CODEN: USXXCO LANGUAGE: English CLASS: 424093200;
A61K-048/00A; C12N-005/06B; C12N-015/867B

- end of record -

?

Display 4/3/3 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.:
2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

?

S (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND (RESIDUE (3N) 260 OR POSIT
 >>>File 5 processing for VIR? stopped at VIROMAX
 >>>File 155 processing for VIR? stopped at VIRUMIN
 >>>File 73 processing for VIR? stopped at VIRUSTOMYCIN
 Processed 10 of 39 files ...
 >>>File 144 processing for VIR? stopped at VIRTUOZO
 Processing
 >>>File 50 processing for VIR? stopped at VIRUSVAKTSINOI
 Completed processing all files

| | |
|---------|---------------------------------------|
| 6497 | LCMV |
| 283843 | LYMPHOCYTIC |
| 16208 | CHORIOMENINGITIS |
| 6354634 | VIR? |
| 10155 | LYMPHOCYTIC(N)CHORIOMENINGITIS(N)VIR? |
| 762448 | RESIDUE |
| 115021 | 260 |
| 223 | RESIDUE (3N) 260 |
| 1842774 | POSITION |
| 115021 | 260 |
| 235 | POSITION (3N) 260 |
| 266453 | PHENYLALANINE |
| 115021 | 260 |
| 29 | PHENYLALANINE (3N) 260 |

S5 51 (LCMV OR LYMPHOCYTIC (N) CHORIOMENINGITIS (N) VIR?) AND
 (RESIDUE (3N) 260 OR POSITION (3N) 260 OR PHENYLALANINE
 (3N) 260)

?

S S5 AND PSEUDOTYP?
 51 S5
 11588 PSEUDOTYP?
 S6 4 S5 AND PSEUDOTYP?

?

Display 6/3/1 (Item 1 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)
 (c) 2005 American Chemical Society. All rts. reserv.

142476299 CA: 142(26)476299z PATENT
Methods for producing and using in vivo pseudotyped retroviruses using
envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for
human gene delivery
 INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen
 LOCATION: USA
 PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609
 APPLICATION: US 2004993319 (20041119) *US 2003718262 (20031120)
 PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO
 LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;
 C07K-014/005B; C12N-015/86B

- end of record -

?

Display 6/3/2 (Item 2 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)
 (c) 2005 American Chemical Society. All rts. reserv.

142476282 CA: 142(26)476282p PATENT

Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery

INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050112096 A1 DATE: 20050526

APPLICATION: US 2003718262 (20031120)

PAGES: 25 pp. CODEN: USXXCO LANGUAGE: English CLASS: 424093200;
A61K-048/00A; C12N-005/06B; C12N-015/867B

- end of record -

?

Display 6/3/3 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0372996 DBR Accession No.: 2005-18702 PATENT

Transducing a nervous system cell with a transgene comprises contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene - virus vector expression in host cell for use in disease therapy and gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L; STEIN C

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L; STEIN C 2005

PATENT NUMBER: US 20050123517 PATENT DATE: 20050609 WPI ACCESSION NO.:
2005-416924 (200542)

PRIORITY APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

NATIONAL APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

LANGUAGE: English

- end of record -

?

Display 6/3/4 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.:
2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

S S1 AND (FIV OR FELINE (N) IMMUNODEFICIENCY)

174 S1

12052 FIV
86340 FELINE
1115638 IMMUNODEFICIENCY
13520 FELINE (N) IMMUNODEFICIENCY
S7 18 S1 AND (FIV OR FELINE (N) IMMUNODEFICIENCY)

?

RD S7

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S8 11 RD S7 (unique items)

?

Display 8/3/1 (Item 1 from file: 5)

DIALOG(R)File 5: BIOSIS Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0014569971 BIOSIS NO.: 200300524868

**TRANSGENE - SPECIFIC TOXICITY IN LENTIVIRAL VECTOR - TRANSDUCED FELINE TM
IN VIVO**

AUTHOR: Loewen N A (Reprint); Teo W (Reprint); Fautsch M P; Bahler C K;

Johnson D H; Poeschla E M (Reprint)

AUTHOR ADDRESS: Molecular Medicine, Mayo Foundation, Rochester, MN, USA**
USA

JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2003 p
Abstract No. 1147 2003 2003

MEDIUM: cd-rom

CONFERENCE/MEETING: Annual Meeting of the Association for Research in
Vision and Ophthalmology Fort Lauderdale, FL, USA May 04-08, 2003;
20030504

SPONSOR: Association for Research in Vision and Ophthalmology

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

-more-

?

Display 8/3/1 (Item 1 from file: 5)

DIALOG(R)File 5: BIOSIS Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

RECORD TYPE: Abstract

LANGUAGE: English

- end of record -

?

Display 8/3/2 (Item 1 from file: 154)

DIALOG(R)File 154: MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

18202725 PMID: 15727934

**The lymphocytic choriomeningitis virus envelope glycoprotein targets
lentiviral gene transfer vector to neural progenitors in the murine brain.**

Stein Colleen S; Martins Ines; Davidson Beverly L

Program in Gene Therapy, Department of Internal Medicine, University of
Iowa College of Medicine, Iowa City, IA 52242, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (
United States) Mar 2005, 11 (3) p382-9, ISSN 1525-0016

Journal Code: 100890581

Contract/Grant No.: DK54759; DK; NIDDK; NS34568; NS; NINDS
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

- end of record -

?

Display 8/3/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

142476299 CA: 142(26)476299z PATENT

Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) for human gene delivery

INVENTOR(AUTHOR): McCray, Paul B.; Davidson, Beverly L.; Stein, Colleen
LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050123517 A1 DATE: 20050609

APPLICATION: US 2004993319 (20041119) *US 2003718262 (20031120)

PAGES: 26 pp., Cont.-in-part of U.S. Ser. No. 718,262. CODEN: USXXCO

LANGUAGE: English CLASS: 424093200; A61K-048/00A; C12N-007/00B;

C07K-014/005B; C12N-015/86B

- end of record -

?

Display 8/3/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

139080197 CA: 139(6)80197w PATENT

Retroviral hybrid vectors pseudotyped with lymphocytic choriomeningitis virus and used for gene therapy

INVENTOR(AUTHOR): Von Laer, Meike-dorothee; Beyer, Winfried

LOCATION: Germany,

ASSIGNEE: Heinrich-Pette-Institute

PATENT: United States ; US 6589763 B1 DATE: 20030708

APPLICATION: US 718096 (20001122) *DE 19856463 (19981126) *US 309572
(19990511) *EP 99250415 (19991125)

PAGES: 65 pp., Cont.-in-part of U.S. Ser. No. 309,572. CODEN: USXXAM

LANGUAGE: English CLASS: 435069100; C12P-021/06A; C12N-015/63B;

C12N-015/00B; C07H-021/04B; C07K-001/00B

- end of record -

?

Display 8/3/5 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

133027363 CA: 133(3)27363x PATENT

Pseudotyping retroviral vectors by replacing the envelope glycoprotein with the lymphocytic choriomeningitis virus glycoprotein to increase host cell range

INVENTOR(AUTHOR): Von Laer, Meike-dorothee

LOCATION: Germany,

ASSIGNEE: Heinrich-Pette-Institut

PATENT: European Pat. Appl. ; EP 1006196 A2 DATE: 20000607
APPLICATION: EP 99250415 (19991125) *DE 19856463 (19981126)
PAGES: 69 pp. CODEN: EPXXDW LANGUAGE: German CLASS: C12N-015/867A;
C12N-005/10B; C12N-007/01B; A61K-048/00B; C07K-014/08B; C12N-015/40B
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO

- end of record -

?

Display 8/3/6 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2005 Inst for Sci Info. All rts. reserv.

13082956 Genuine Article#: 833DM No. References: 0
Title: Improved apical airway epithelia targeting properties of FIV vector pseudotyped with envelopes from LCMV
Author(s): Dylla DE; Hickey MA; Michele DE; Davidson BL; Campbell KP; McCray PB
Corporate Source: Univ Iowa, Program Gene Therapy, Iowa City//IA/
Journal: MOLECULAR THERAPY, 2004, V9, 1 (MAY), PS186-S186
ISSN: 1525-0016 Publication date: 20040500
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
Language: English Document Type: MEETING ABSTRACT

- end of record -

?

Display 8/3/7 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE
(c) 2005 Elsevier Science B.V. All rts. reserv.

11857703 EMBASE No: 2002429700
No false start for novel pseudotyped vectors
Sanders D.A.
D.A. Sanders, Department of Biological Sciences, Purdue University, West Lafayette, IN 47907 United States
AUTHOR EMAIL: retrovir@bragg.bio.purdue.edu
Current Opinion in Biotechnology (CURR. OPIN. BIOTECHNOL.) (United Kingdom) 01 OCT 2002, 13/5 (437-442)
CODEN: CUOBE ISSN: 0958-1669
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 41

- end of record -

?

Display 8/3/8 (Item 1 from file: 266)

DIALOG(R)File 266:FEDRIP
Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00624119
IDENTIFYING NO.: 2P01HL051670-11 0005 AGENCY CODE: CRISP
Targeting Entry in Epithelia with ICMV-FIV
PRINCIPAL INVESTIGATOR: MCCRAY, PAUL B, JR
ADDRESS: PAUL-MCCRAY@UIOWA.EDU UNIVERSITY OF IOWA 616 MEDICAL RESEARCH CENTER IOWA CITY, IA 52242
PERFORMING ORG.: UNIVERSITY OF IOWA, IOWA CITY, IOWA

SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
DATES: 2009/01/97 TO 2003/31/09 FY : 2004

- end of record -

?

Display 8/3/9 (Item 1 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0372996 DBR Accession No.: 2005-18702 PATENT

Transducing a nervous system cell with a transgene comprises contacting the cell with a pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus strain WE-54 envelope glycoprotein and the transgene - virus vector expression in host cell for use in disease therapy and gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L; STEIN C

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L; STEIN C 2005

PATENT NUMBER: US 20050123517 PATENT DATE: 20050609 WPI ACCESSION NO.:
2005-416924 (200542)

PRIORITY APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

NATIONAL APPLIC. NO.: US 993319 APPLIC. DATE: 20041119

LANGUAGE: English

- end of record -

?

Display 8/3/10 (Item 2 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0371801 DBR Accession No.: 2005-17507 PATENT

New pseudotyped retrovirus virion (especially feline immunodeficiency virus) comprising a Lymphocytic choriomeningitis virus (LCMV) strain WE-54 envelope glycoprotein, useful for treating a human airway epithelial cell - retro virus vector-mediated gene transfer and expression in airway epithelium cell, central nervous system cell or a hepatocyte cell for use in gene therapy

AUTHOR: MCCRAY P B; DAVIDSON B L

PATENT ASSIGNEE: MCCRAY P B; DAVIDSON B L 2005

PATENT NUMBER: US 20050112096 PATENT DATE: 20050526 WPI ACCESSION NO.:
2005-371617 (200538)

PRIORITY APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

NATIONAL APPLIC. NO.: US 718262 APPLIC. DATE: 20031120

LANGUAGE: English

- end of record -

?

Display 8/3/11 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0329671 DBR Accession No.: 2004-01963 PATENT

New chimeric Ebola envelope protein comprising a functional Ebola glycoprotein binding domain fused to a heterologous amino acid sequence, useful for inducing an immune response against Ebola virus, bacteria, or fungi - involving vector-mediated gene transfer and expression in host cell for use in therapy

AUTHOR: WILSON J M; MEDINA M F C; KOBINGER G

PATENT ASSIGNEE: UNIV PENNSYLVANIA 2003
PATENT NUMBER: WO 200392582 PATENT DATE: 20031113 WPI ACCESSION NO.:
2004-011795 (200401)
PRIORITY APPLIC. NO.: US 427752 APPLIC. DATE: 20021120
NATIONAL APPLIC. NO.: WO 2003US11494 APPLIC. DATE: 20030428
LANGUAGE: English

- end of record -

?

| Ref | Items | Index-term |
|-----|-------|-------------------------|
| E1 | 2 | AU=MCCRAY, PATRICK DALE |
| E2 | 3 | AU=MCCRAY, PAUL |
| E3 | 2 | *AU=MCCRAY, PAUL B |
| E4 | 10 | AU=MCCRAY, PAUL B JR |
| E5 | 9 | AU=MCCRAY, PAUL B. |
| E6 | 2 | AU=MCCRAY, PAUL B. JR. |
| E7 | 96 | AU=MCCRAY, PAUL B., JR. |
| E8 | 7 | AU=MCCRAY, PAUL B., JR |
| E9 | 4 | AU=MCCRAY, PAUL B, JR |
| E10 | 1 | AU=MCCRAY, PAUL M., JR. |
| E11 | 2 | AU=MCCRAY, PAULA |
| E12 | 5 | AU=MCCRAY, PB |

Enter P or PAGE for more

?

| Ref | Items | Index-term |
|-----|-------|---------------------|
| E1 | 4 | AU=MCCRAY P.B. |
| E2 | 76 | AU=MCCRAY P.B. JR. |
| E3 | 6 | *AU=MCCRAY PAUL |
| E4 | 85 | AU=MCCRAY PAUL B |
| E5 | 136 | AU=MCCRAY PAUL B JR |
| E6 | 4 | AU=MCCRAY PAUL M |
| E7 | 140 | AU=MCCRAY PB |
| E8 | 1 | AU=MCCRAY PC |
| E9 | 3 | AU=MCCRAY PD |
| E10 | 2 | AU=MCCRAY PERCY |
| E11 | 2 | AU=MCCRAY PL |
| E12 | 2 | AU=MCCRAY PM |

Enter P or PAGE for more

?

| Ref | Items | Index-term |
|-----|-------|---------------------------|
| E1 | 1 | AU=DAVIDSON, BEVERLY L. |
| E2 | 1 | AU=DAVIDSON, BEVERLEY L. |
| E3 | 7 | *AU=DAVIDSON, BEVERLY |
| E4 | 22 | AU=DAVIDSON, BEVERLY L |
| E5 | 186 | AU=DAVIDSON, BEVERLY L. |
| E6 | 4 | AU=DAVIDSON, BEVERLY LONG |
| E7 | 1 | AU=DAVIDSON, BH |
| E8 | 4 | AU=DAVIDSON, BILL |
| E9 | 1 | AU=DAVIDSON, BILLY |
| E10 | 1 | AU=DAVIDSON, BILLY H. |
| E11 | 1 | AU=DAVIDSON, BIRGITTA |
| E12 | 7 | AU=DAVIDSON, BJ |

Enter P or PAGE for more

?

| Ref | Items | Index-term |
|-----|-------|-------------------------|
| E1 | 3 | AU=DAVIDSON BETH TOWERY |
| E2 | 8 | AU=DAVIDSON BEVERLEY L |
| E3 | 31 | *AU=DAVIDSON BEVERLY |
| E4 | 371 | AU=DAVIDSON BEVERLY L |
| E5 | 2 | AU=DAVIDSON BG |
| E6 | 3 | AU=DAVIDSON BH |
| E7 | 1 | AU=DAVIDSON BI |
| E8 | 2 | AU=DAVIDSON BINYAMIN |
| E9 | 68 | AU=DAVIDSON BJ |
| E10 | 2 | AU=DAVIDSON BK |
| E11 | 5 | AU=DAVIDSON BKS |
| E12 | 329 | AU=DAVIDSON BL |

Enter P or PAGE for more

?